- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04651088
Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet
Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet
Study Overview
Status
Conditions
Detailed Description
Kidney stones are a common medical problem, occurring in almost 10% of people in the United States1. Furthermore, 50% of patients will recur within 10 years2. Metabolic testing is advised in recurrent stone formers, as well as those considered high risk, to assess for a specific abnormality which may prompt intervention to prevent future stone formation. Non-surgical interventions include both dietary counselling, as well as pharmacotherapy.
One of the most commonly prescribed class of pharmacotherapies is alkali therapy which can be used to both increase the urinary pH and raise the urine citrate levels. This is particularly useful as correction of very acidic urinary pH (<5.5) can counteract uric acid crystallization thereby preventing or even dissolving uric acid stones3. Further, citrate has been shown to be a potent inhibitor of calcium stones by binding to the calcium directly4 and inhibiting crystal nucleation, thereby reducing calcium stone formation5,6.
The most commonly utilized preparation of alkali therapy is potassium citrate which has been shown to prevent stone formation better than sodium citrate7. Unfortunately, some forms of potassium citrate (crystal packets) have become unavailable, and the slow release form of potassium citrate (UroCit-K) now exceeds $15/day in cost8. There have been multiple alternative alkali therapies that have been used in place of potassium citrate, including both medical foods and prescription medications, but with little evidence to support their use. A pilot study in order to quantify the metabolic effects of these agents and compare them to potassium citrate will be performed.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Margaret Pearle
- Phone Number: 214-648-6853
- Email: margaret.pearle@utsouthwestern.edu
Study Contact Backup
- Name: Jessica Dai
- Email: jessica.dai@utsouthwestern.edu
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Contact:
- Margaret Pearle
- Phone Number: 214-648-6853
- Email: margaret.pearle@utsouthwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18 and older.
- with or without a history of stone disease.
Exclusion Criteria:
- They are unable to take any of the medications due to health reasons.
- Participants are pregnant or nursing.
- Participants are unable to adhere to the metabolic diet.
- Participants had a prior adverse event from one or more of the medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sodium Bicarbonate
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
Placebo Comparator: Metabolic diet
Controlled metabolic diet arm.
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
Active Comparator: Potassium citrate
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
Active Comparator: Litholyte arm
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
Active Comparator: Crystal Lite
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
Active Comparator: Potassium Bicarbonate
|
Slow release potassium citrate UroCit-K.
Participants will take 20mEq twice daily.
650mg tabs.
Take 3 tabs twice daily.
One packet is taken with 170ml of water.
Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24 hour urine volume
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Total urine volume
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine volume
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Total urine volume
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine creatinine
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine creatinine
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine creatinine
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine creatinine
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine calcium
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
urine calcium
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine calcium
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
urine calcium
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine potassium
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine potassium
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine potassium
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine potassium
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine sodium
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine sodium
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine sodium
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine sodium
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hours urine citrate
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine citrate
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine citrate
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine citrate
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hours urine uric acid
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine uric acid
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine uric acid
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine Uric Acid
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hours urine oxalate
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine oxalate
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine oxalate
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine oxalate
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hours urine magnesium
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine magnesium
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine magnesium
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine magnesium
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hours urine ammonia
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine ammonia
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hours urine ammonia
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine ammonia
|
Change from baseline (Day 4) to end of study (day 12)
|
24 Hour Urine pH
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Overal Urine pH from 24h urine sample.
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 Hour Urine pH
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Overal Urine pH from 24h urine sample.
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine phosphorus
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine phosphorus
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine phosphorus
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine phosphorus
|
Change from baseline (Day 4) to end of study (day 12)
|
24 hour urine sulfate
Time Frame: Change from baseline (Day 4) to initial start on treatment (Day 5)
|
Urine sulfate
|
Change from baseline (Day 4) to initial start on treatment (Day 5)
|
24 hour urine sulfate
Time Frame: Change from baseline (Day 4) to end of study (day 12)
|
Urine sulfate
|
Change from baseline (Day 4) to end of study (day 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
# of patient who adherence to 100% Medication
Time Frame: At the end of study approximately 10 weeks after start of study.
|
Patient's adherence to medication for duration of study.
|
At the end of study approximately 10 weeks after start of study.
|
Total out of pocket cost
Time Frame: At the end of study approximately 10 weeks after start of study.
|
Calculate and compare treatment costs for the different interventions (in American dollars).
|
At the end of study approximately 10 weeks after start of study.
|
Patient's Satisfaction Survey
Time Frame: At the end of study approximately 10 weeks after start of study.
|
Patient satisfaction survey, adapted from the Treatment Satisfaction Questionnaire for Medication-14.
Patients are queried on their satisfaction, with 9 questions for each medication.
|
At the end of study approximately 10 weeks after start of study.
|
Patient's GI Distress
Time Frame: At the end of study approximately 10 weeks after start of study.
|
Patient's GI distress symptom scale measures patients GI distress.
There are 18 questions with descriptive answers ranging from "none", "mild", "moderate", "quite a lot" and "unbearable".
There are no numerical scores, rather just descriptive scores.
"None" means no GI distress, "unbearable" means that you are in a lot of distress from your GI symptoms.
|
At the end of study approximately 10 weeks after start of study.
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. doi: 10.1016/j.eururo.2012.03.052. Epub 2012 Mar 31.
- Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997 Dec;158(6):2069-73. doi: 10.1016/s0022-5347(01)68155-2.
- Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol. 1997;15(3):155-64. doi: 10.1007/BF02201852. No abstract available.
- Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3. doi: 10.1016/s0022-5347(17)46963-1.
- Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986 Sep;30(3):422-8. doi: 10.1038/ki.1986.201.
- Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989 Dec 15;111(12):1006-9. doi: 10.7326/0003-4819-111-12-1006.
- Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation. Medical management of kidney stones: AUA guideline. J Urol. 2014 Aug;192(2):316-24. doi: 10.1016/j.juro.2014.05.006. Epub 2014 May 20.
- Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988 Feb;139(2):240-2. doi: 10.1016/s0022-5347(17)42374-3.
- Stern KL, Canvasser N, Borofsky M, Gleason VM, Kamphuis G, El Tayeb MM, Hsi R, Scotland KB. Alkalinizing Agents: A Review of Prescription, Over-the-Counter, and Medical Food Supplements. J Endourol. 2020 Jan;34(1):1-6. doi: 10.1089/end.2019.0292. Epub 2019 Sep 25.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Pathological Conditions, Anatomical
- Urolithiasis
- Urinary Calculi
- Calculi
- Nephrolithiasis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Calculi
- Physiological Effects of Drugs
- Natriuretic Agents
- Diuretics
- Respiratory System Agents
- Expectorants
- Potassium Citrate
Other Study ID Numbers
- STU-2020-0613
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stone
-
Washington University School of MedicineRecruiting
-
Société Internationale d'UrologieCompletedStone Ureter | Stone, Kidney | Stone;RenalUnited States, China, Korea, Republic of, Malaysia, Saudi Arabia, Greece, India, Indonesia, Iran, Islamic Republic of, Iraq, Kenya, Romania, South Africa, Taiwan, Turkey
-
Wake Forest University Health SciencesCogenix Medical CorporationWithdrawnKidney Stone | Renal Stone | Ureter StoneUnited States
-
Advance Shockwave Technology GmbHUnknownKidney StonesUnited States
-
Mansoura UniversityCompletedUrologic Diseases | Stone, Kidney | Stone, Urinary | ESWL | Radiolucent Calculus of Urinary Tract | DissolutionEgypt
-
University of British ColumbiaActive, not recruiting
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Selcuk UniversityThe Scientific and Technological Research Council of TurkeySuspendedKidney StonesTurkey
-
Mansoura UniversityCompleted
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom
Clinical Trials on Potassium citrate
-
Advicenne PharmaTerminatedDistal Renal Tubular AcidosisUnited States, Canada
-
National Center for Research Resources (NCRR)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...CompletedKidney Calculi | Hypercalciuria
-
University of Texas Southwestern Medical CenterCompleted
-
Kantonsspital Baselland BruderholzCompleted
-
University of ZurichUniversity of Texas Southwestern Medical Center; Swiss Federal Institute of...CompletedBone Disease | Metabolic Acidosis | Physical Capacity | Renal Transplant Patients | Mineral MetabolismSwitzerland
-
University of Texas Southwestern Medical CenterCompleted
-
University of Texas Southwestern Medical CenterWithdrawnHypertension | Pre-hypertensionUnited States
-
Weill Medical College of Cornell UniversityCompletedBone Diseases, Metabolic | Osteoporosis, PostmenopausalUnited States
-
European Georges Pompidou HospitalInstitut National de la Santé Et de la Recherche Médicale, France; Sponsor...CompletedGlomerulonephritis | Cystinuria | Renal Lithiasis | Interstitial NephritisFrance